ArticleJTCVS open2026
Evaluation of dual-lumen pulmonary artery cannulation in extracorporeal right ventricular support.
Article in JTCVS open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate whether dual-lumen (DL) versus single-lumen (SL) pulmonary artery cannulation improves outcomes in patients with refractory right ventricular failure (RVF) supported with extracorporeal life support and to identify which patients benefit most. Methods: We conducted a multicenter retrospective cohort study using the international PLACE registry (2000-2020). Adults undergoing pulmonary artery cannulation for isolated RVF were included. Outcomes were in-hospital and 30-day mortality, bleeding, thromboembolic events, continuous renal-replacement therapy, and length of stay. Propensity score weighting was applied to adjust for baseline differences. Prespecified analyses tested effect modification by hypoxemia, renal function, platelet count, cannulation site, and oxygenator use. Mediation and clustering were used to explore physiological pathways and phenotypes. Results: Among 345 patients, DL cannulation was associated with lower postoperative lactate and creatinine and with fewer bleeding events. In weighted multivariable models, DL reduced the risk of bleeding and the composite of bleeding or thromboembolism (weighted odds ratio, 0.50; 95% CI 0.32-0.77; Conclusions: In extracorporeal life support for RVF, DL pulmonary artery cannulation improves outcomes primarily by enhancing early organ function and reducing complications. Patients with baseline hypoxemia appear to benefit most, supporting a physiology-guided approach to cannulation strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.